The FDA approved nemolizumab (Nemluvio) in combination with prescription topical agents for the treatment of ...

For some people, keeping up with eczema treatments can be difficult, but resources are available to help find relief from the ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

The clinical trial is for a new drug for people with moderate to severe eczema, the NHS trust says The first UK patient has been recruited to take part in a clinical trial for a new drug for ...

In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was ...

At the age of four, Joel Godfrey's eczema was wreaking ... Joel's life has been transformed by a new ointment called tacrolimus which is based on an anti-rejection drug used in transplants.

Nonspecific anti-inflammatories like steroids might be entirely sidelined for mild-to-moderate chronic hand eczema now that three targeted topical agents are available.

Health Minister Mark Butler has struck a deal to secure the place of a “life-changing” eczema treatment on the Pharmaceutical ...

“Red light therapy is an energy-based modality that uses specific wavelengths of red and near-infrared light (typically ...

KKH and the National Skin Centre say there are more such patients, but no recent studies have been done. Read more at ...

Dec 11 (Reuters) - AnaptysBio (ANAB.O), opens new tab said on Wednesday it would end the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.